Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease

BACKGROUND AND AIMS: Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn’s disease (CD), has reduced direct drug costs. Though clinicians are comfortable with biosimilar use in treatment-naïve patients, there are concerns in some jurisdictions that there a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernard, Edmond-Jean, Fedorak, Richard N., Jairath, Vipul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369127/
https://www.ncbi.nlm.nih.gov/pubmed/31970610
http://dx.doi.org/10.1007/s10620-019-06036-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369127/
https://www.ncbi.nlm.nih.gov/pubmed/31970610
http://dx.doi.org/10.1007/s10620-019-06036-0

Ejemplares similares